交银国际作为联席全球协调人助力宝济药业完成港股IPO项目

交银国际2025-12-11

企业融资业务12月10日，上海宝济药业股份有限公司（“宝济药业”，2659.HK）在香港联交所主板挂牌上市。宝济药业本次全球发售定价每股26.38港元，发行37,911,700股H股，融资规模约为10.00亿港元。交银国际担任联席全球协调人、联席账簿管理人兼联席牵头经办人，全程高效助力宝济药业顺利登陆港股资本市场。宝济药业成立于2019年，战略性聚焦四大领域：(i) 大容量皮下给药，(ii) 抗体...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2590519099?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-11 21:41","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2590519099","market":"hk","top_or_hot":-1,"title":"交银国际作为联席全球协调人助力宝济药业完成港股IPO项目","media":"交银国际","content":"<div>\n<p>企业融资业务12月10日，上海宝济药业股份有限公司（“宝济药业”，2659.HK）在香港联交所主板挂牌上市。宝济药业本次全球发售定价每股26.38港元，发行37,911,700股H股，融资规模约为10.00亿港元。交银国际担任联席全球协调人、联席账簿管理人兼联席牵头经办人，全程高效助力宝济药业顺利登陆港股资本市场。宝济药业成立于2019年，战略性聚焦四大领域：(i) 大容量皮下给药，(ii) 抗体...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211214729a699b2f3&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>交银国际作为联席全球协调人助力宝济药业完成港股IPO项目</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n交银国际作为联席全球协调人助力宝济药业完成港股IPO项目\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-11 21:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211214729a699b2f3&s=b><strong>交银国际</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>企业融资业务12月10日，上海宝济药业股份有限公司（“宝济药业”，2659.HK）在香港联交所主板挂牌上市。宝济药业本次全球发售定价每股26.38港元，发行37,911,700股H股，融资规模约为10.00亿港元。交银国际担任联席全球协调人、联席账簿管理人兼联席牵头经办人，全程高效助力宝济药业顺利登陆港股资本市场。宝济药业成立于2019年，战略性聚焦四大领域：(i) 大容量皮下给药，(ii) 抗体...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211214729a699b2f3&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1147","symbol_name":"投资银行业与经纪业","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211214729a699b2f3&s=b","article_id":"2590519099","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211214729a699b2f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590519099","pubTimestamp":1765460485,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"宝济药业本次全球发售定价每股26.38港元，发行37,911,700股H股，融资规模约为10.00亿港元。交银国际担任联席全球协调人、联席账簿管理人兼联席牵头经办人，全程高效助力宝济药业顺利登陆港股资本市场。宝济药业已布局多个治疗领域的自主管线，拥有12款自主开发的在研和上市产品。通过将稳健的生产体系与前瞻性的研发能力深度融合，宝济药业已形成“创新研发—生物制造—临床转化”一体化的全产业链布局。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1147":"投资银行业与经纪业","02659":"宝济药业-B","03329":"交银国际"},"translate_title":"BoCom International serves as the joint global coordinator to help Baoji Pharmaceutical complete the Hong Kong stock IPO project","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1.5,"03329":1.5},"content_text":"企业融资业务12月10日，上海宝济药业股份有限公司（“宝济药业”，2659.HK）在香港联交所主板挂牌上市。宝济药业本次全球发售定价每股26.38港元，发行37,911,700股H股，融资规模约为10.00亿港元。交银国际担任联席全球协调人、联席账簿管理人兼联席牵头经办人，全程高效助力宝济药业顺利登陆港股资本市场。宝济药业成立于2019年，战略性聚焦四大领域：(i) 大容量皮下给药，(ii) 抗体介导的自身免疫性疾病，(iii) 辅助生殖；及 (iv) 重组生物制药。宝济药业已布局多个治疗领域的自主管线，拥有12款自主开发的在研和上市产品。通过将稳健的生产体系与前瞻性的研发能力深度融合，宝济药业已形成“创新研发—生物制造—临床转化”一体化的全产业链布局。据弗若斯特沙利文数据显示，到2033年，上述四大战略领域在中国的临床可触及市场规模合计将达约人民币500亿元。项目执行过程中，交银国际充分发挥其在医疗健康领域的深度洞察与丰富的行业内项目执行经验，依托强大的销售网络，积极开展市场推广、锁定基石订单，为公司香港上市项目的圆满成功提供有力支持和坚实保障。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590519099","isCrawlerRequest":true}